Shorted
Firebrick Pharma logo
FRE
Pharmaceuticals, Biotechnology & Life Sciences

Firebrick Pharma

Short interest
0.01%
+0.01 pp 30d
as of 1 July 2026
Reported shorts
19.2K
Shares on issue
285.199M

Firebrick Pharma (FRE) company profile

Profile, insiders and operations

Company

AI-generated research profile of Firebrick Pharma

pharmaceuticals
biotechnology
nasal spray
povidone-iodine
ASX

Firebrick Pharma is a pharmaceutical development and manufacturing company focused on developing and commercializing nasal sprays based on povidone-iodine (PVP-I). Their lead product, Nasodine Nasal Spray, is intended as a treatment for the common cold. The company aims to bring Nasodine to the global market.

Director trades

10 trades recorded

DateDirectorTypeSharesPriceValue
2026-05-21Peter Molloy
buy
---
2026-05-21Stephen Goodall
buy
---
2026-05-20Peter Laurence Molloy
buy
245,000$0.040$9,856.02
2026-05-20Stephen Francis Goodall
buy
110,000$0.046$5,060
2024-10-10Stephen Francis Goodall
buy
181,818$0.055$10,000
2024-10-10Peter Laurence Molloy
buy
454,545$0.055$25,000
2024-10-10Stephen Goodall
buy
---
2024-10-10Peter Molloy
buy
---
2024-06-28Peter Molloy
buy
---
2024-06-27Peter Laurence Molloy
buy
500,000$0.057$28,437.74

FRE intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required